AI Article Synopsis

  • The updated EAU Guidelines recommend adjuvant pembrolizumab for high-risk operable clear cell Renal Cell Carcinoma (ccRCC) but raise concerns about potential overtreatment and undertreatment of patients based on their risk levels.
  • The review highlights challenges in accurately identifying high-risk tumors due to interobserver variability among pathologists and discusses the need for better prognostic assessment systems.
  • It suggests that molecular biomarkers may improve patient prognostication in the future by helping to better identify those with a more severe prognosis.

Article Abstract

Introduction: The updated European Association of Urology (EAU) Guidelines issued a weak recommendation for adjuvant pembrolizumab for patients with high-risk operable clear cell Renal Cell Carcinoma (ccRCC). High risk of recurrence was defined, as per protocol-criteria, as T2 with nuclear grade 4 or sarcomatoid differentiation, T3 or higher, regional lymph node metastasis, or stage M1 with no evidence of disease. Considering the heterogeneous population included in the recommendation, it has been questioned if adjuvant pembrolizumab may lead to overtreatment of some patients as well as undertreatment of patients with worse prognosis.

Areas Covered: In this review, we discuss the issues related to the assessment of pathological features required to identify those patients harboring a high-risk tumor, highlighting the issue related to interobserver variability and discuss the currently available prognostic scoring systems in ccRCC.

Expert Opinion: PPathologist assessment of prognostic features suffers from interobserver variability which may depend on gross sampling and the pathologist's expertise. The presence of clear cell feature is not sufficient criteria by itself to define ccRCC since clear cell can be also found in other histotypes. Application of molecular biomarkers may be useful tools in the near future to help clinicians identify patients harboring tumors with worse prognosis.

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2022.2145952DOI Listing

Publication Analysis

Top Keywords

clear cell
12
adjuvant pembrolizumab
8
identify patients
8
patients harboring
8
interobserver variability
8
patients
5
hot topics
4
topics renal
4
renal cancer
4
cancer pathology
4

Similar Publications

Carthamus tinctorius L. (Safflower) is widely used in traditional Japanese, Korean, Chinese, Arabian, and Persian herbal medicine to treat metabolic diseases. This study aimed to characterize C.

View Article and Find Full Text PDF

Mutation of genes related to the SWI/SNF chromatin remodeling complex is detected in 20% of all cancers. The SWI/SNF chromatin remodeling complex comprises about 15 subunits and is classified into three subcomplexes: cBAF, PBAF, and ncBAF. Previously, we showed that ovarian clear cell carcinoma cells deficient in ARID1A, a subunit of the cBAF complex, are synthetic lethal with several genes required for glutathione (GSH) synthesis and are therefore sensitive to the GSH inhibitor eprenetapopt (APR-246).

View Article and Find Full Text PDF

Background: A precise observation is that the cervix's solid tumors possess hypoxic regions where the oxygen concentration drops below 1.5%. Hypoxia negatively impacts the host's immune system and significantly diminishes the effectiveness of several treatments, including radiotherapy and chemotherapy.

View Article and Find Full Text PDF

Induced membrane technique (IMT) is a new method for repairing segmental bone defects. However, the mechanism of its defect repair is not clear. In recent years, several studies have gradually indicated that ferroptosis is closely related to bone remodeling.

View Article and Find Full Text PDF

Vimentin is a ubiquitination and degradation substrate of the ubiquitin ligase KPC1.

Biochem Biophys Res Commun

December 2024

The Rappaport Faculty of Medicine and Research Institute, and the Rappaport Technion Integrated Cancer Center (R-TICC), Technion-Israel Institute of Technology, Haifa, 3109601, Israel. Electronic address:

The ubiquitin proteasome system (UPS), driven by ubiquitin as a degradation signal, eliminates, in a highly specific manner, 'abnormal' proteins and proteins that completed their function. This process involves a hierarchical cascade of E1, E2, and E3 enzymes. The E3 ubiquitin ligases, act as specific receptors that bind their cognate substrates.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!